Comparative effects of biologics on cardiovascular risk among older patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 75, Issue 10, 2016, Pages 1813-1818

  Zhang, Jie ^a   Xie, Fenglong ^b   Yun, Huifeng ^a,b   Chen, Lang ^b   Muntner, Paul ^a   Levitan, Emily B ^a   Safford, Monika M ^c   Kent, Shia T ^a   Osterman, Mark T ^d   Lewis, James D ^d   Saag, Kenneth ^b   Singh, Jasvinder A ^b,e,f   Curtis, Jeffrey R ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e BIRMINGHAM VA MEDICAL CENTER   (United States)

^f Mayo Clinic College of Medicine   (United States)

Author keywords

Cardiovascular Disease; DMARDs (biologic); Rheumatoid Arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MIDDLE AGED; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMPARATIVE STUDY; COMPLICATION; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ABATACEPT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CARDIOVASCULAR DISEASES; ETANERCEPT; FEMALE; HUMANS; INCIDENCE; INFLIXIMAB; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84956684746     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-207870     Document Type: Article

References (23)

1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
2. Kremers HM, Crowson CS, Therneau TM, et al. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum 2008;58:2268-74.
3. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
4. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:3790-8.
5. Greenberg JD, Kremer JM, Curtis JR, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
6. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-18.
7. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008;10: R30.
8. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007;56:2905-12.
9. Vegh E, Vancsa A, Kerekes G, et al. A1.83 Long-term effects of etanercept and certolizumab pegol treatment on vascular function and lipid parameters in rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 2014;73(Suppl 1): A36-7.
10. Kirkham BW, Wasko MC, Hsia EC, et al. Effects of golimumab, an anti-tumour necrosis factor-α human monoclonal antibody, on lipids and markers of inflammation. Ann Rheum Dis 2014;73:161-9.
11. Jin T, Bokarewa M, Amu S, et al. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. Clin Exp Rheumatol 2009;27:491-4.
12. Raterman HG, Levels H, Voskuyl AE, et al. HDL protein composition alters from proatherogenic into less atherogenic and proinflammatory in rheumatoid arthritis patients responding to rituximab. Ann Rheum Dis 2013;72:560-5.
13. Mathieu S, Couderc M, Glace B, et al. Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. Biologics 2013;7:259-64.
14. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141.
15. Curtis JR, Perez-Gutthann S, Suissa S, et al. on behalf of the Actemra Pharmacoepidemiology B. Tocilizumab in rheumatoid arthritis: a case study of safety evaluations of a large postmarketing data set from multiple data sources. Semin Arthritis Rheum 2014;44:381-8.
16. Kent ST, Safford MM, Zhao H, et al. Optimal Use of Available Claims to Identify a Medicare Population Free of Coronary Heart Disease. Am J Epidemiol 2015;182:808-19.
17. Kiyota Y, Schneeweiss S, Glynn RJ, et al. Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 2004;148:99-104.
18. Ljung L, Askling J, Rantapää-Dahlqvist S, et al. The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. Arthritis Res Ther 2014; 16:R127.
19. Carmona L, Descalzo MA, Perez-Pampin E, et al, BIOBADASER and EMECAR Groups. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007;66:880-5.
20. Masson P, Henderson L, Chapman JR, et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014;11:CD010699.
21. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96.
22. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
23. Cutrona SL, Toh S, Iyer A, et al. Validation of acute myocardial infarction in the Food and Drug Administration's Mini-Sentinel program. Pharmacoepidemiol Drug Saf 2013;22:40-54.